Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Cancer Prev Res (Phila). 2015 Jun 30;8(9):864–872. doi: 10.1158/1940-6207.CAPR-15-0029

Serum SAMe. (a) Serum SAMe at all study time points among subjects randomized to SAMe or placebo shows that SAMe increased significantly among subject receiving SAMe, but not among subjects receiving placebo, and that serum SAMe level returned to baseline by Week 30. (b) Serum SAMe levels increased between Week 0 and Week 24 among subject randomized to SAMe at all study sites, but did not increase among subjects randomized to placebo.

Serum SAMe. (a) Serum SAMe at all study time points among subjects randomized to SAMe or placebo shows that SAMe increased significantly among subject receiving SAMe, but not among subjects receiving placebo, and that serum SAMe level returned to baseline by Week 30. (b) Serum SAMe levels increased between Week 0 and Week 24 among subject randomized to SAMe at all study sites, but did not increase among subjects randomized to placebo.